Learn everything you need to know about Saxagliptin and Metformin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, ...

June 27, 2011 (San Diego, California) — Saxagliptin demonstrated reductions in glycosylated hemoglobin (HbA 1c) and fasting plasma glucose that were similar to those seen with the sulfonylurea drug ...

ONGLYZATM (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control in Treatment Naive ...

BOSTON — Use of saxagliptin (Onglyza, AstraZeneca), a dipeptidyl peptidase-4 (DPP-4) inhibitor for type 2 diabetes, was not associated with an increase in cancer incidence or cancer-related death ...

ORLANDO, Fla.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results up to 76-weeks from a Phase 3 study of ONGLYZA ™ (saxagliptin) as initial ...

The warnings on labels will come after FDA reviewed long-term safety data. FDA has announced it will add a warning to the labels for saxagliptin and alogliptin, as well as combination therapies ...

HealthDay News — For patients with type 2 diabetes, saxagliptin is associated with improvement in the albumin/creatinine ratio (ACR), according to a study published online in Diabetes Care. Ofri ...

Review the side-effects of Saxagliptin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

SAN DIEGO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from an investigational Phase 3b clinical study which reported that ONGLYZA ™ ...

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE ™ ...

The FDA is looking into a possible association between type 2 diabetes medication saxagliptin and heart failure. The drug was not associated with a higher risk of death. Saxagliptin, also known as ...

Results from an interim analysis of a long-term Phase 3 study at 102 weeks with ONGLYZA™ (saxagliptin), an investigational, selective, reversible inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme ...